ClinicalTrials.Veeva

Menu

Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

A

Assiut University

Status and phase

Enrolling
Phase 3

Conditions

Sepsis

Treatments

Other: 0.9% saline
Drug: Tranexamic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT04910464
17300607

Details and patient eligibility

About

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

Full description

A written informed consent will be taken from the patients or their relatives.Patients will be assigned randomly to two groups (40 subjects each) with qSOFA ≥2.

In (Group T) administer 1 gram of tranexamic acid (TXA) in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of tranexamic acid (TXA) IV over 8 hours in 0.9% normal saline for the first 3 days. In (Group C) administer the same volume (100 ml normal saline)and same duration (first three days)for controlled patients.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
  • & needed ICU admission.

Exclusion criteria

  • Chronic renal failure
  • Liver cirrhosis
  • Bleeding disorders or current anticoagulant therapy
  • Pregnancy or breastfeeding
  • Impaired color vision
  • Severe vascular ischemia, history of venous thrombosis & pulmonary embolism
  • Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
  • Allergy to tranexamic acid (TXA)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups, including a placebo group

Tranexamic acid
Experimental group
Description:
Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.
Treatment:
Drug: Tranexamic acid
Saline placebo
Placebo Comparator group
Description:
Give the same volume (100 ml normal saline) and same duration (first three days).
Treatment:
Other: 0.9% saline

Trial contacts and locations

1

Loading...

Central trial contact

Omar Soliman

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems